Cooley advised Spruce Biosciences, Inc., a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, on the separation of the company’s CRHX-101 (formerly SPR-202) program into Adrenyx Biosciences, Inc., a newly formed wholly-owned subsidiary of Spruce that will operate as a dedicated endocrinology company.
Cooley Advises Spruce Biosciences on Separation of its CRHX-101 Program into Adrenyx Biosciences